(BFLY) Butterfly Network - Overview
Stock: Ultrasound Device, Probe, Software, Cloud, Education
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 117% |
| Relative Tail Risk | -17.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -55.44 |
| Character TTM | |
|---|---|
| Beta | 2.292 |
| Beta Downside | 2.034 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.01% |
| CAGR/Max DD | 0.15 |
Description: BFLY Butterfly Network December 27, 2025
Butterfly Network, Inc. (NYSE:BFLY) designs, manufactures, and sells handheld ultrasound devices-most notably the Butterfly iQ+ and iQ3-that combine whole-body imaging with a smartphone or tablet interface. The product suite also includes specialty probes (e.g., iQ+ Bladder), a veterinary version (iQ+ Vet), and a subscription-based software platform that offers cloud storage, teleguidance, and educational content through Butterfly Academy and ScanLab. Distribution is mixed: a direct sales force, third-party distributors, and e-commerce channels deliver the hardware and recurring-revenue services to clinicians, health systems, and veterinarians worldwide.
Key quantitative signals (as of FY 2023) include revenue of roughly $210 million, representing a 30 % year-over-year increase, and a gross margin near 70 % driven by the high-margin software subscription model. The point-of-care ultrasound market is projected to grow at a CAGR of 12 % to exceed $5 billion by 2028, buoyed by telehealth adoption, cost-containment pressures in hospitals, and expanding use in primary-care and emergency settings. A material risk factor is the competitive landscape-large incumbents such as Philips and GE are accelerating their own handheld ultrasound rollouts, which could compress pricing or increase customer acquisition costs.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on BFLY’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -79.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 11.80 > 1.0 |
| NWC/Revenue: 216.0% < 20% (prev 205.6%; Δ 10.42% < -1%) |
| CFO/TA -0.09 > 3% & CFO -24.9m > Net Income -79.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.1m) vs 12m ago 18.48% < -2% |
| Gross Margin: 43.24% > 18% (prev 0.30%; Δ 4295 % > 0.5%) |
| Asset Turnover: 31.86% > 50% (prev 28.73%; Δ 3.12% > 0%) |
| Interest Coverage Ratio: -54.79 > 6 (EBITDA TTM -69.7m / Interest Expense TTM 1.43m) |
Altman Z'' -15.00
| A: 0.66 (Total Current Assets 241.4m - Total Current Liabilities 50.3m) / Total Assets 290.0m |
| B: -2.98 (Retained Earnings -863.9m / Total Assets 290.0m) |
| C: -0.28 (EBIT TTM -78.5m / Avg Total Assets 277.6m) |
| D: -10.03 (Book Value of Equity -863.9m / Total Liabilities 86.2m) |
| Altman-Z'' Score: -17.82 = D |
Beneish M -3.63
| DSRI: 1.02 (Receivables 24.4m/20.6m, Revenue 88.4m/76.2m) |
| GMI: 0.68 (GM 43.24% / 29.60%) |
| AQI: 0.57 (AQ_t 0.06 / AQ_t-1 0.11) |
| SGI: 1.16 (Revenue 88.4m / 76.2m) |
| TATA: -0.19 (NI -79.9m - CFO -24.9m) / TA 290.0m) |
| Beneish M-Score: -3.63 (Cap -4..+1) = AAA |
What is the price of BFLY shares?
Over the past week, the price has changed by -14.65%, over one month by -16.75%, over three months by +50.22% and over the past year by -23.18%.
Is BFLY a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BFLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.1 | 49.7% |
| Analysts Target Price | 5.1 | 49.7% |
| ValueRay Target Price | 3.6 | 5% |
BFLY Fundamental Data Overview February 03, 2026
P/B = 5.143
Revenue TTM = 88.4m USD
EBIT TTM = -78.5m USD
EBITDA TTM = -69.7m USD
Long Term Debt = 21.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.62m USD (from shortTermDebt, last quarter)
Debt = 21.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -123.2m USD (from netDebt column, last quarter)
Enterprise Value = 877.1m USD (1.00b + Debt 21.0m - CCE 144.2m)
Interest Coverage Ratio = -54.79 (Ebit TTM -78.5m / Interest Expense TTM 1.43m)
EV/FCF = -31.87x (Enterprise Value 877.1m / FCF TTM -27.5m)
FCF Yield = -3.14% (FCF TTM -27.5m / Enterprise Value 877.1m)
FCF Margin = -31.12% (FCF TTM -27.5m / Revenue TTM 88.4m)
Net Margin = -90.31% (Net Income TTM -79.9m / Revenue TTM 88.4m)
Gross Margin = 43.24% ((Revenue TTM 88.4m - Cost of Revenue TTM 50.2m) / Revenue TTM)
Gross Margin QoQ = -17.48% (prev 63.68%)
Tobins Q-Ratio = 3.02 (Enterprise Value 877.1m / Total Assets 290.0m)
Interest Expense / Debt = 1.83% (Interest Expense 385.0k / Debt 21.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -62.0m (EBIT -78.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.80 (Total Current Assets 241.4m / Total Current Liabilities 50.3m)
Debt / Equity = 0.10 (Debt 21.0m / totalStockholderEquity, last quarter 203.8m)
Debt / EBITDA = 1.77 (negative EBITDA) (Net Debt -123.2m / EBITDA -69.7m)
Debt / FCF = 4.48 (negative FCF - burning cash) (Net Debt -123.2m / FCF TTM -27.5m)
Total Stockholder Equity = 211.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.77% (Net Income -79.9m / Total Assets 290.0m)
RoE = -37.80% (Net Income TTM -79.9m / Total Stockholder Equity 211.3m)
RoCE = -33.79% (EBIT -78.5m / Capital Employed (Equity 211.3m + L.T.Debt 21.0m))
RoIC = -29.35% (negative operating profit) (NOPAT -62.0m / Invested Capital 211.3m)
WACC = 14.09% (E(1.00b)/V(1.02b) * Re(14.36%) + D(21.0m)/V(1.02b) * Rd(1.83%) * (1-Tc(0.21)))
Discount Rate = 14.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.28%
Fair Price DCF = unknown (Cash Flow -27.5m)
EPS Correlation: 83.99 | EPS CAGR: 49.27% | SUE: 0.95 | # QB: 1
Revenue Correlation: 59.32 | Revenue CAGR: 3.36% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.05 | Chg30d=+0.003 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.14 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+15.4% | Growth Revenue=+17.0%